You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《滬深兩市》上證午後向好全日升約1% 銀保券商地產股上揚
內地疫情反覆,昨日(17日)新增本土確診病例2,388例,新增本土無症狀感染者1,742例。人民銀行今日(18日)進行300億元人民幣(下同)7天期逆回購操作,單日淨投放200億元。中美兩國元首今晚通電話 商討中美關係及俄烏等問題。人民幣兌美元中間價今下調19點。上證今早低開後反覆偏軟,深成及創板跌幅較大,午後各指數在銀行、保險及地產股帶動下轉升,上證升幅較爲明顯。 上證全日升36點或1.1%,收報3,251點;深成指全日升38點或0.3%,收報12,328點;創業板指數微升3點或0.1%,收報2,713點,成交2,357億元。上證深成全日成交分別爲4,284億元及5,621億元。 重磅金融、銀行、券商及保險股走高,工行(601398.SH)及建行(601939.SH)分別升0.7%及2%。交行(601328.SH)升3.4%。券商股華創陽安(600155.SH)漲停。華鑫股份(600621.SH)升2.4%。 中國平安(601318.SH)去年純利跌29%至1,016.18億元遜預期,股價升5.3%。國壽(601628.SH)及太保(601601.SH)分別升3.1%及3%。 地產、建築股走高,陽光城(000671.SZ)、保利發展(600048.SH)、金地集團(600383.SH)漲停。金科股份(000656.SZ)及萬科(000002.SZ)分別升3.6%及4.6%。先鋒新材(300163.SZ)及浙江建設(002761.SZ)漲停。 白酒股回軟,龍頭股貴州茅臺(600519.SH)及五糧液(000858.SZ)分別跌0.7%及0.2%。 華海藥業(600521.SH)、普洛藥業(000739.SZ)、復星醫藥(600196.SH)、九洲藥業(603456.SH)獲允許生產輝瑞新冠口服藥Paxlovid成分之一奈瑪特韋(nirmatrelvir)原料藥或製劑。相關股份個別發展,復星醫藥升2.5%,普洛藥業靠穩微升0.2%,華海藥業及九洲藥業分別跌4.7%及4.4%。 工信部發布2022年汽車標準化工作要點提出,研究發佈汽車芯片標準體系,啓動電動車動力蓄電池安全標準修訂工作。惟相關龍頭芯片鋰電池股走疲,贛鋒鋰業(002460.SZ)跌0.6%。寧德時代(300750.SZ)回吐2.7%。比亞迪(002594.SZ)亦微跌0.2%。 國際油價反彈,中石油(601857.HK)升2.3%。(ta/u) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account